You are here

Herzuma Approved for Treatment of Breast Cancer

New Biosimilar Provides Broader Treatment Options for Patients

The FDA has approved another biosimilar for the adjuvant treatment of HER2 overexpressing, node-positive or node-negative breast cancer. In addition, this biosimilar Herzuma (trastuzumab-pkrb, Celltrion, South Korea, and Teva Pharmaceutical, Israel) is approved as part of a first-line treatment for metastatic breast cancer combined with chemotherapy.

Common adverse events associated with the use of trastuzumab-pkrb for treatment of HER2-positive breast cancers include diarrhea, headache, chills, nausea, fever, infection, insomnia, congestive heart failure, cough and rash. Serious adverse effects can include worsening of chemotherapy-induced neutropenia.

Like its reference product trastuzumab (Herceptin, Genentech), trastuzumab-pkrb carries a boxed warning about elevated risks for cardiomyopathy, infusion reactions, pulmonary toxicity, and embryo-fetal toxicity.

Source:, December 17, 2018

More Headlines

iPSC Therapy Designed to Salvage Eye, Prevent Vision Loss
Health Outcomes Have No Improvement
Adjunctive Therapy is First Generic Version of Sabril for Focal Seizures
Targeted Antibody for FGR3-Positive Mutation
Method Could Lead to Manufacturing Corneas for Transplants
First and Only Second-Generation TKI for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Potential Life-Saving Device Can be Implanted in 2-LB Babies
New Therapy for Patients With HCC Who Previously Received Nexavar
Aggressive Disease Represents Around 6% of All New Cases of NHL